×
About 19,428 results

ALLMedicine™ Acute Lymphoblastic Leukemia Center

Research & Reviews  6,512 results

Progress in Transplants for Acute Lymphoblastic Leukemia.
https://doi.org/10.1158/1078-0432.CCR-21-3959
Clinical Cancer Research : an Official Journal of the Ame... Gale RP

Jan 15th, 2022 - Hematopoietic cell transplants are used to treat some adults with acute lymphoblastic leukemia, especially those with high-risk features, such as those with BCR::ABL1. This strategy may be changing given the safety and efficacy of modern tyrosine ...

Levofloxacin prophylaxis for pediatric leukemia patients: Longitudinal follow-up for im...
https://doi.org/10.1002/pbc.29525
Pediatric Blood & Cancer; Davis A, Stevens AM et. al.

Jan 15th, 2022 - Bloodstream infections (BSIs) cause morbidity and mortality in pediatric patients with leukemia. Antibiotic prophylaxis during periods of chemotherapy-induced neutropenia may reduce the incidence of BSIs. A levofloxacin prophylaxis guideline was i...

20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positi...
https://doi.org/10.1158/1078-0432.CCR-21-2675
Clinical Cancer Research : an Official Journal of the Ame... Bazarbachi A, Labopin M et. al.

Jan 14th, 2022 - Relapse after allogeneic hematopoietic cell transplantation (allo-HCT) remains the first cause of transplant failure in patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). In other hematologic malignancies, therapeutic ad...

see more →

Guidelines  4 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelin...
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.

Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
https://doi.org/10.6004/jnccn.2017.0147
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.

Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...

Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment...
https://doi.org/10.1016/j.bbmt.2011.12.585
Biology of Blood and Marrow Transplantation : Journal of ... Oliansky DM, Camitta B et. al.

Jan 3rd, 2012 - Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. T...

see more →

Drugs  119 results see all →

Clinicaltrials.gov  282 results

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
https://clinicaltrials.gov/ct2/show/NCT05192889

Jan 14th, 2022 - This is a non-randomized phase I/II clinical trial. In Block I, all patients receiving common therapy evaluating the activity of combination chemotherapy with venetoclax and navitoclax in children with relapsed or refractory acute lymphoblastic le...

Leukemia-Specific Immune Cells (BAFFR- CAR T Cells) for the Treatment of Relapsed or Refractory B-cell ALL
https://clinicaltrials.gov/ct2/show/NCT04690595

Jan 12th, 2022 - This phase I trial evaluates the side effects and best dose of BAFFR-CAR T cells in treating patients with B-cell Acute Lymphoblastic Leukemia that has come back (recurrent) or does not respond to treatment (refractory). T cells are infection figh...

Postural Control Under Different Cognitive Loads in Adult Survivors of Acute Lymphoblastic Leukemia and Age-Matched Healthy Individuals
https://clinicaltrials.gov/ct2/show/NCT03581045

Jan 11th, 2022 - Cognitive performance (attention and working memory) will be evaluated using the auditory N-Back test. The 0-back condition and the 2-back condition will be used. After cognitive assessment, participants will perform 3 different postural control t...

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
https://clinicaltrials.gov/ct2/show/NCT03016377

Jan 11th, 2022 - LCCC1541-ATL is a Phase I/Phase II dose finding trial to determine if chimeric antigen receptor T (CAR-T) cells targeting the CD19 antigen and containing the inducible caspase 9 safety switch can be safely administered to adult and pediatric subje...

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BC...
https://clinicaltrials.gov/ct2/show/NCT05182385

Jan 10th, 2022 - Transfer of patients to alloHSCT after one cycle or after a subsequent cycle is considered as per protocol discontinuation and as premature treatment discontinuation. There will be a safety follow-up visit at 30 days after end of the last infusion...

see more →

News  852 results

Improved Survival in ALL Patients Who Relapse After Transplant
https://www.medscape.com/viewarticle/966558

Jan 13th, 2022 - A transplant offers a chance of a cure from leukemia, but when the transplant is not successful, such patients are left with few other options and a poor prognosis. But the management of such patients has been improving, and over the past 20 years...

Liquid Biopsy Field Moves Forward But Faces Hurdles
https://www.onclive.com/view/liquid-biopsy-field-moves-forward-but-faces-hurdles

Jan 3rd, 2022 - Advancements are rapidly expanding the potential uses for blood-based liquid biopsies, but broad clinical adoption in cancer care hinges on improving the knowledge base of practicing oncologists and gathering prospective data to validate assays, a...

Practice-Changing Data From 2021 Sets Tone for New Year
https://www.onclive.com/view/practice-changing-data-from-2021-sets-tone-for-new-year

Dec 23rd, 2021 - Throughout 2021, investigators of several pivotal trials presented findings that may result in shifting standards for the treatment of patients across tumor types. Published papers and presentations at several key meetings generated debates in seq...

Examining the Development of T-cell Acute Lymphoblastic Leukemia
https://www.onclive.com/view/examining-the-development-of-t-cell-acute-lymphoblastic-leukemia

Dec 23rd, 2021 - T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive type of leukemia. Despite advances in treatments, patients have an extremely poor prognosis, highlighting the need to explore the genetic components that lead to the formation of T-ALL, ...

Novel Immunotherapy for Cancer Takes Cue From Transplant Rejection
https://www.medscape.com/viewarticle/964898

Dec 16th, 2021 - NEW YORK (Reuters Health) - A novel immunotherapy treatment works by triggering genetically modified T cells to reject cancer, much as they would a transplanted organ, researchers say. The approach was effective in mouse models and in leukemia cel...

see more →

Patient Education  2 results see all →